GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
发明人:
SATHE, Rajendra S.,CLARK, William M.
申请号：
PE0027652016
公开号：
PE01462017A1
申请日:
2015.06.23
申请国别(地区):
PE
年份:
2017
代理人:
摘要：
Refers to a Crystalline form of succinate Salt of (S) - 6 - ((1 - acetilpiperidin - 4-yl) amino) - N - (3 - (3,4 dihidroisoquinolin - 2 (1H) - yl) - 2-hydroxypropyl) pirimidino - 4 - carboxamide, whose x-ray diffraction patterns Powder (drxp) to 2 (Theta) are: 4.5\u00b0, 8.2\u00b0, 10.4\u00b0, 13.5\u00b0, 15.8\u00b0, 16. Fourth, 17.3\u00b0, 17.7\u00b0, 18.1\u00b0, 18.8\u00b0, 19.6\u00b0, 20.8\u00b0, 21.9\u00b0, 23.3\u00b0 and 24.0\u00b0 (0.2\u00b0.It also relates to a Crystalline form of the benzoate Salt of (S) - 6 - ((1 - acetilpiperidin - 4-yl) amino) - N - (3 - (3,4 dihidroisoquinolin - 2 (1H) - yl) - 2-hydroxypropyl) pirimidino - 4 - carboxamide. Also refers to a Pharmaceutical Composition and a method of treatment. These Crystalline forms inhibit Protein arginine METHYLTRANSFERASe 5 (PRMT5), being useful in the treatment of cancer.Se refiere a una forma cristalina de la sal succinato de (S)-6-((1-acetilpiperidin-4-il)amino)-N-(3-(3,4-dihidroisoquinolin 2(1H)-il)-2-hidroxipropil)pirimidino-4-carboxamida, cuyos patrones de difraccion de rayos X en polvo (DRXP) en cuanto a 2(theta) son: 4.5°, 8.2°, 10.4°, 13.5°, 15.8°, 16.4°, 17.3°, 17.7°, 18.1°, 18.8°, 19.6°, 20.8°, 21.9°, 23.3° y 24.0° ± 0.2°. Tambien se refiere a una forma cristalina de la sal benzoato de (S)-6-((1-acetilpiperidin-4-il)amino)-N-(3-(3,4-dihidroisoquinolin 2(1H)-il)-2-hidroxipropil)pirimidino-4-carboxamida. Ademas se refiere a una composicion farmaceutica y a un metodo de tratamiento. Dichas formas cristalinas inhiben la proteina arginina metiltransferasa 5 (PRMT5), siendo utiles en el tratamiento del cancer.
